Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CSPG4/HMW-MAA/MCSP/NG2 Antibody (R3V07)

Catalog #:   RHJ08301 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM
Accession: Q6UVK1
Overview

Catalog No.

RHJ08301

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400

Target

Chondroitin sulfate proteoglycan 4, CSPG4, Chondroitin sulfate proteoglycan NG2, MCSP, Melanoma chondroitin sulfate proteoglycan, Melanoma-associated chondroitin sulfate proteoglycan

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q6UVK1

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3V07

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HEK293 cells using CSPG4 mouse mAb (green) and negative control (red).
References

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma., PMID:39409881

CSPG4-targeting CAR-macrophages inhibit melanoma growth., PMID:38895447

Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy., PMID:38735753

MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance., PMID:37990493

CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate., PMID:37432459

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma., PMID:37208128

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4., PMID:37185332

VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen., PMID:36768830

The role of pericytes on the efficacy of bevacizumab in colorectal cancer., PMID:36422502

Generation and Characterization of Native and Sialic Acid-Deficient IgE., PMID:36362241

The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma., PMID:36140259

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy., PMID:36110930

Identification of Novel Retinal Pericyte-Targeting rAAV Vectors Through Directed Evolution., PMID:36018583

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers., PMID:35891187

Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial., PMID:35580930

A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET., PMID:35239034

Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation., PMID:34942534

Receptor binding mechanisms of Clostridioides difficile toxin B and implications for therapeutics development., PMID:34862749

In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart., PMID:34513315

A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model., PMID:34318902

Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection., PMID:34145250

Immunoaffinity-Based Isolation of Melanoma Cell-Derived and T Cell-Derived Exosomes from Plasma of Melanoma Patients., PMID:33704724

Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression., PMID:33613873

BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes., PMID:33404293

Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice., PMID:33346907

Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas., PMID:32599896

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma., PMID:32331483

In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model., PMID:31769737

Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027., PMID:31578248

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B., PMID:31233493

Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance., PMID:31230410

Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma., PMID:31217827

Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade., PMID:31128201

Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice., PMID:30956944

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors., PMID:30625226

Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism., PMID:30340601

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins., PMID:29565434

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models., PMID:29561763

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types., PMID:29375561

Resident cell lineages are preserved in pulmonary vascular remodeling., PMID:29359814

Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage., PMID:29196603

Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4., PMID:29036679

Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display., PMID:28981720

Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants., PMID:28842504

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL., PMID:28657611

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy., PMID:28287848

Development and validation of a cell-based fluorescent method for measuring antibody affinity., PMID:28024998

Isolating subpopulations of human epidermal basal cells based on polyclonal serum against trypsin-resistant CSPG4 epitopes., PMID:28011196

Roles of chondroitin sulfate proteoglycan 4 in fibrogenic/adipogenic differentiation in skeletal muscle tissues., PMID:27582000

Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand., PMID:27448975

Datasheet
$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CSPG4/HMW-MAA/MCSP/NG2 Antibody (R3V07) [RHJ08301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only